FDA Grants Priority Review to Insmed's ARIKAYCE sNDA for MAC Lung Disease
INSM sits 39% above its 52-week low of $90.39.
Summary
The FDA granted Priority Review to Insmed's supplemental New Drug Application for ARIKAYCE in newly diagnosed MAC lung disease, with a PDUFA target action date of January 28, 2027. Priority Review shortens the review clock to six months, signaling the agency sees the application as addressing an unmet need. This follows the sNDA submission noted in the Q2 10-Q and builds on ARIKAYCE's existing approval for refractory MAC. A positive decision would expand the label to a larger patient population, potentially adding a second growth driver alongside the recently launched BRINSUPRI. The January 28, 2027 PDUFA date is the key upcoming catalyst.
At the time of this announcement, INSM was trading at $125.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.2B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.